Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2010

View Archived Issues

Promising phase Ib data on TD-101 in pachyonychia congenita / News in Context

Targeting gut-derived serotonin synthesis shows therapeutic potential in osteoporosis

Suven Life Sciences discloses novel 5-HT6 receptor ligands

Novel antibacterial compounds identified by Korean scientists

Pfizer presents new 5-HT2C receptor agonists with antiobesity potential

Aeolus begins second preclinical study of AEOL-10150 for acute radiation syndrome

Proximagen grants Upsher-Smith rights to tonabersat for epilepsy in North America

Clinical data disclosed on gabapentin enacarbil in restless legs syndrome

Roche discloses new therapeutics for type 2 diabetes

Oral torezolid phosphate safe in phase II trial in complicated skin/skin structure infection

Merck & Co. presents novel CGRP receptor antagonists

Astellas claims new inhibitors of Rho-associated protein kinase

Malaysian scientists disclose new rosamine analogues for cancer therapy

RXi and miRagen to collaborate on miRNA-based agents

MolMed's NGR-hTNF enters phase III in malignant pleural mesothelioma

Neurocrine begins second phase I clinical trial of VAT2 inhibitor NBI-98854 in Canada

Roche acquires Medingo and expands position in insulin delivery systems market

Critical Outcome Technologies provides update on HIV-1 integrase program

InterMune reports topline phase IIb danoprevir data in hepatitis C

Mersana and Teva Pharmaceutical collaborate on development of XMT-1107

Catalyst signs agreement with NIDA for phase IIb vigabatrin trial for cocaine addiction

Aeras and Crucell begin phase II trial of tuberculosis vaccine in HIV-infected adults

Adeona reports data on Zinthionein ZC in Alzheimer's disease and mild cognitive impairment

FDA announces phaseout dates for CFC-containing inhalers

Metabolex and Takeda enter research collaboration for biological products